Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Substance Abuse Treatment, Prevention, and Policy
Published in: Substance Abuse Treatment, Prevention, and Policy 1/2019

Open Access 01-12-2019 | Naloxone | Debate

Higher doses of naloxone are needed in the synthetic opioid era

Authors: Ronald B. Moss, Dennis J. Carlo

Published in: Substance Abuse Treatment, Prevention, and Policy | Issue 1/2019

Login to get access

Abstract

There has been a dramatic increase of deaths due to illicit fentanyl. We examined the pharmacology of fentanyl and reviewed data on the number of repeat doses of naloxone used to treat fentanyl overdoses. Multiple sequential doses of naloxone have been required in a certain percentage of opioid overdoses due to fentanyl. In addition, fentanyl appears to differ from other opioids as having a very rapid onset with high systemic levels found in overdose victims. A rapid competition is required by naloxone to out-compete large numbers of opioid receptors occupied by fentanyl in the CNS. Taken together, we propose that higher doses of naloxone are needed to combat the new era of overdoses due to the more potent synthetic opioids such as fentanyl.
Literature
1.
2.
3.
Seth P, Rudd RA, Noona RK, Haegerich TM. Quantifying the epidemic of prescription opioid overdose deaths. AJPH April. 2018;108(4).
4.
5.
Schumann H, Erickson T, Thompson TM, Zautcke JL, Denton JL. Fentanyl epidemic in Chicago, Illinois and surrounding Cook County. Clin Toxicol. 2008;46(6):501–6.CrossRef
6.
7.
Somerville NJ, O’Donnell J, Gladden RM, Zibbell JE, Green TC, Younkin M, Ruiz S, Babakhanlou-Chase H, Chan M, Callis BP, Kuramoto-Crawford J, Nields HM, Walley AY. MMWR / April 14, 2017 / Vol. 66 / No. 14.
8.
Fairbairn N, Coffin PO, Walley AY. Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: challenges and innovations responding to a dynamic epidemic. Int J Drug Policy. 2017;46:172–9.CrossRef
9.
Handal KA, Schauben JL, Salamone FR. Naloxone. Ann Emerg Med. 1983;12(7):438–45.CrossRef
10.
Sarton E, Teppema L, Dahan A. Naloxone reversal of opioid induced respiratory depression with special emphasis on the partial agonist/antagonist buprenorphine. Ad Exp Med Biol. 2008;605:486–91.CrossRef
11.
Tyndale RF, Sellers EM. Opioids: the painful public health reality. Clinical Pharmacology & Therapeutics. 2018;103(6):924–35.CrossRef
12.
Way EL, Loh HH. Responsivity To Naloxone During Morphine Dependence. Annals NY Academy of Sciences. 1976;281:252–61.CrossRef
13.
Dahan A, Aarts L, Smith TW. Incidence, reversal, and prevention of opioid-induced respiratory depression. Anesthesiology. 2010;112:226–38.CrossRef
14.
Wong B, Perkins MW, Tressler J, Rodriguez A, Devorak J, Sciuto AM. Effects of inhaled aerosolized carfentanil on real-time physiological responses in mice: a preliminary evaluation of naloxone. Inhal Toxicol. 2017;29(2):65–74.CrossRef
15.
Freise KJ, Newbound GC, Tudan C, Clark TP. Naloxone reversal of an overdose of a novel, long-acting transdermal fentanyl solution in laboratory beagles. J Vet Pharmacol Ther. 2012;35(Suppl 2):45–51.CrossRef
16.
Brown JH, Pleuvry BJ. Antagonism of the respiratory effects of Alfentanil and Fentanil by naloxone in the conscious rabbit. Br J Anaesth. 1981;53(10):1033–7.CrossRef
17.
Drummond GB, Davie IT, Scott DB. Naloxone: dose-dependent antagonism of respiratory depression by fentanyl in anaesthetized patients. BJA: British Journal of Anaesthesia. 1977;49(2):151–4.CrossRef
18.
19.
MacKenzie M, Zed PJ, Ensom MHH. Opioid pharmacokinetics-pharmacodynamics: clinical implications in acute pain Management in Trauma. Annals of pharmacology. 2016;50(3):209–18.CrossRef
20.
Kuczynska K, Grzonkowski P, Kacprzak L, Zawilska JB. Abuse of fentanyl: an emerging problem to face. Forensic Sci Int. 2018;289:207–14.CrossRef
21.
Stanley TH. The fentanyl story, the journal of pain, Vol 15. No. 2014;12(December):1215–26.
22.
23.
24.
Sutter ME, Gerona RR, Davis MT, Roche BM, Colby DK, Chenoweth JA, Adams AJ, Owen KP, Ford JB, Black HB, Albertson TE. Fatal fentanyl: one pill can kill. Acad Emerg Med. 2017;24:106–13.CrossRef
25.
Tomassoni AJ, Hawk KF, Jubanyik K, Nogee DP, Durant T, Lynch KL, Patel R, Dinh D, Ulrich A, D’Onofrio G. Multiple fentanyl overdoses — New Haven, Connecticut, June 23, 2016. MMWR. 2017;66(4):107–11.PubMed
26.
Fogarty MF, Papsun DM, Logan BK. Analysis of Fentanyl and 18 Novel Fentanyl. Analogs and Metabolites by LC–MS-MS, and report of Fatalities Associated with Methoxyacetylfentanyl and Cyclopropylfentanyl. J Anal Toxicol. 2018:1–13.
27.
Lotsch J, Walter C, Parnham MJ, Oertel BG, Geisslinger G. Pharmacokinetics of non-intravenous formulations of fentanyl. Clin Pharmacokinet. 2013;52:23–36.CrossRef
28.
Heishman SJ, Stitzer ML, Bigelow GE, Liebson IA. Acute opioid physical dependence in Postaddict humans: naloxone dose effects after brief morphine exposure. J Pharmacol Exp Ther. 1989;248(1).
29.
Gal TJ. Naloxone reversal of buprenorphine-induced respiratory depression. Clin Pharmacol and Ther. 1989;45:66–71.CrossRef
30.
Faul M, Lurie P, Kinsman JM, Dailey MW, Crabaugh C, Sasser SM. Multiple naloxone administrations among emergency medical service providers is increasing. Prehospital Emergency Care. 21(4):411–9.
31.
Klebacher R, Harris MI, Ariyaprakai N, Tagore A, Robbins V, Dudley LS, Bauter R, Koneru S, Hill RD, Wasserman E, Shanes A, Merlin MA. Incidence of Naloxone Redosing. in the Age of the New Opioid Epidemic. Prehosp Emerg Care. 2017;21(6):682–7.CrossRef
32.
Marco CA, Trautman W, Cook A, Mann D, Rasp J, Perkins O, Ballester M. naloxone use among emergency department patients with opioid overdose. The Journal of Emergency Medicine. 2018;55(1):64–70.CrossRef
33.
Wong B, Perkins MW, Tressler J, Rodriguez A, Devorak J, Sciuto AM. Effects of inhaled aerosolized carfentanil on real-time physiological responses in mice: a preliminary evaluation of naloxone. Inhal Toxicol. 29(2):65–74.
34.
Narcan Summary Basis of Approval, https://​www.​accessdata.​fda.​gov/​drugsatfda_​docs/​summary_​review/​2017/​208411s001SumR.​pdf
35.
36.
37.
38.
Lynn RR, Galinkin JL. Naloxone dosage for opioid reversal: current evidence and clinical implications. Ther Adv Drug Saf. 2018;9(1):63–88.CrossRef
Metadata
Title
Higher doses of naloxone are needed in the synthetic opioid era
Authors
Ronald B. Moss
Dennis J. Carlo
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Substance Abuse Treatment, Prevention, and Policy / Issue 1/2019
Electronic ISSN: 1747-597X
DOI
https://doi.org/10.1186/s13011-019-0195-4

Other articles of this Issue 1/2019

Substance Abuse Treatment, Prevention, and Policy 1/2019 Go to the issue

Research

Evaluation of methanol content of illegal beverages using GC and an easier modified Chromotropic acid method; a cross sectional study

Research

Concurrent psychiatry for patients enrolled in opioid agonist treatment: a propensity score matched cohort study in Ontario Canada

Research

Gambling symptoms, behaviors, and cognitive distortions in Japanese university students

Research

Current practices and perceived implementation barriers for working with alcohol prevention in occupational health services: the WIRUS OHS study

Research

Help seeking behavior for problematic substance uses in north-West Ethiopia

Research

The exploration of factors related to treatment retention in Narcotics Anonymous members: a qualitative study